Edesa Income Tax Expense vs Gross Profit Analysis

EDSA Stock

USD 4.48 0.20 4.27%

Edesa Biotech financial indicator trend analysis is much more than just examining Edesa Biotech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Edesa Biotech is a good investment. Please check the relationship between Edesa Biotech Income Tax Expense and its Gross Profit accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

Income Tax Expense vs Gross Profit

Income Tax Expense vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Edesa Biotech Income Tax Expense account and Gross Profit. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Edesa Biotech's Income Tax Expense and Gross Profit is -0.43. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Edesa Biotech, assuming nothing else is changed. The correlation between historical values of Edesa Biotech's Income Tax Expense and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Edesa Biotech are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Income Tax Expense i.e., Edesa Biotech's Income Tax Expense and Gross Profit go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Income Tax Expense

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Edesa Biotech minus its cost of goods sold. It is profit before Edesa Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from Edesa Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 872 M, whereas Selling General Administrative is forecasted to decline to about 3.6 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	118.2K	183.5K	165.1K	156.9K
Research Development	13.3M	4.8M	5.5M	4.3M

Cost Of Revenue Research Development

Edesa Biotech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Net Receivables	Property Plant And Equipment Gross	Current Deferred Revenue	Non Current Liabilities Total	Intangible Assets	Common Stock Total Equity	Inventory	Common Stock	Short Term Investments	Other Assets
Total Assets		0.37	0.35	0.75	-0.8	-0.59	0.81	0.41	0.23	0.89	0.2	0.41	0.13	0.26	0.97	0.21	0.32	0.24	-0.37	0.19	0.73	0.44	-0.14	0.6	0.45	0.14
Other Current Liab	0.37		0.99	-0.2	-0.41	-0.28	0.44	0.26	0.22	0.29	0.25	0.16	0.46	0.8	0.33	-0.29	0.13	-0.28	0.08	0.62	-0.1	-0.25	-0.2	0.02	0.05	-0.17
Total Current Liabilities	0.35	0.99		-0.21	-0.4	-0.24	0.43	0.25	0.23	0.27	0.26	0.17	0.44	0.79	0.31	-0.33	0.13	-0.32	0.07	0.6	-0.09	-0.3	-0.21	-0.02	0.09	-0.11
Total Stockholder Equity	0.75	-0.2	-0.21		-0.34	-0.57	0.36	0.44	0.28	0.58	0.25	0.47	0.02	-0.44	0.69	0.32	0.39	0.35	-0.58	-0.48	0.86	0.56	-0.24	0.75	0.66	0.19
Net Debt	-0.8	-0.41	-0.4	-0.34		0.28	-0.99	-0.14	-0.08	-0.82	-0.04	-0.28	-0.02	-0.59	-0.83	0.0	-0.14	0.0	0.1	-0.59	-0.45	-0.17	-0.02	-0.19	-0.04	-0.16
Retained Earnings	-0.59	-0.28	-0.24	-0.57	0.28		-0.32	-0.49	-0.24	-0.53	-0.43	-0.16	-0.63	0.02	-0.53	-0.36	-0.02	-0.41	0.56	0.17	-0.54	-0.57	0.32	-0.93	-0.38	0.49
Cash	0.81	0.44	0.43	0.36	-0.99	-0.32		0.21	0.15	0.81	0.12	0.29	0.09	0.59	0.83	-0.04	0.15	-0.04	-0.15	0.57	0.47	0.15	-0.04	0.23	0.08	0.15
Non Current Assets Total	0.41	0.26	0.25	0.44	-0.14	-0.49	0.21		0.92	0.05	0.88	0.57	0.59	-0.09	0.21	-0.36	0.47	-0.33	-0.75	-0.27	0.39	-0.15	-0.81	0.45	0.64	0.17
Non Currrent Assets Other	0.23	0.22	0.23	0.28	-0.08	-0.24	0.15	0.92		-0.14	0.95	0.61	0.52	-0.09	0.04	-0.66	0.53	-0.63	-0.71	-0.27	0.29	-0.45	-0.89	0.2	0.63	0.32
Cash And Short Term Investments	0.89	0.29	0.27	0.58	-0.82	-0.53	0.81	0.05	-0.14		-0.12	0.11	-0.01	0.37	0.96	0.45	-0.05	0.45	-0.1	0.36	0.62	0.64	0.25	0.51	0.16	-0.05
Common Stock Shares Outstanding	0.2	0.25	0.26	0.25	-0.04	-0.43	0.12	0.88	0.95	-0.12		0.5	0.72	-0.1	0.02	-0.59	0.42	-0.56	-0.72	-0.3	0.27	-0.36	-0.91	0.35	0.58	0.06
Other Current Assets	0.41	0.16	0.17	0.47	-0.28	-0.16	0.29	0.57	0.61	0.11	0.5		0.15	-0.13	0.28	-0.4	0.5	-0.38	-0.62	-0.25	0.41	-0.23	-0.6	0.16	0.59	0.34
Other Stockholder Equity	0.13	0.46	0.44	0.02	-0.02	-0.63	0.09	0.59	0.52	-0.01	0.72	0.15		0.14	0.03	-0.25	0.09	-0.22	-0.37	-0.06	-0.05	-0.13	-0.61	0.44	0.15	-0.51
Total Liab	0.26	0.8	0.79	-0.44	-0.59	0.02	0.59	-0.09	-0.09	0.37	-0.1	-0.13	0.14		0.31	-0.18	-0.13	-0.19	0.35	0.96	-0.27	-0.21	0.17	-0.28	-0.35	-0.08
Total Current Assets	0.97	0.33	0.31	0.69	-0.83	-0.53	0.83	0.21	0.04	0.96	0.02	0.28	0.03	0.31		0.31	0.22	0.33	-0.21	0.27	0.67	0.53	0.05	0.53	0.31	0.09
Property Plant And Equipment Net	0.21	-0.29	-0.33	0.32	0.0	-0.36	-0.04	-0.36	-0.66	0.45	-0.59	-0.4	-0.25	-0.18	0.31		-0.42	1.0	0.1	-0.07	0.24	0.91	0.61	0.46	-0.13	-0.33
Net Receivables	0.32	0.13	0.13	0.39	-0.14	-0.02	0.15	0.47	0.53	-0.05	0.42	0.5	0.09	-0.13	0.22	-0.42		-0.4	-0.28	-0.22	0.13	-0.32	-0.66	0.09	0.36	0.42
Property Plant And Equipment Gross	0.24	-0.28	-0.32	0.35	0.0	-0.41	-0.04	-0.33	-0.63	0.45	-0.56	-0.38	-0.22	-0.19	0.33	1.0	-0.4		0.06	-0.09	0.26	0.92	0.58	0.5	-0.11	-0.34
Current Deferred Revenue	-0.37	0.08	0.07	-0.58	0.1	0.56	-0.15	-0.75	-0.71	-0.1	-0.72	-0.62	-0.37	0.35	-0.21	0.1	-0.28	0.06		0.47	-0.61	-0.07	0.72	-0.57	-0.76	-0.2
Non Current Liabilities Total	0.19	0.62	0.6	-0.48	-0.59	0.17	0.57	-0.27	-0.27	0.36	-0.3	-0.25	-0.06	0.96	0.27	-0.07	-0.22	-0.09	0.47		-0.32	-0.15	0.35	-0.37	-0.5	-0.04
Intangible Assets	0.73	-0.1	-0.09	0.86	-0.45	-0.54	0.47	0.39	0.29	0.62	0.27	0.41	-0.05	-0.27	0.67	0.24	0.13	0.26	-0.61	-0.32		0.49	-0.15	0.66	0.71	0.29
Common Stock Total Equity	0.44	-0.25	-0.3	0.56	-0.17	-0.57	0.15	-0.15	-0.45	0.64	-0.36	-0.23	-0.13	-0.21	0.53	0.91	-0.32	0.92	-0.07	-0.15	0.49		0.46	0.67	0.02	-0.35
Inventory	-0.14	-0.2	-0.21	-0.24	-0.02	0.32	-0.04	-0.81	-0.89	0.25	-0.91	-0.6	-0.61	0.17	0.05	0.61	-0.66	0.58	0.72	0.35	-0.15	0.46		-0.25	-0.55	-0.17
Common Stock	0.6	0.02	-0.02	0.75	-0.19	-0.93	0.23	0.45	0.2	0.51	0.35	0.16	0.44	-0.28	0.53	0.46	0.09	0.5	-0.57	-0.37	0.66	0.67	-0.25		0.46	-0.4
Short Term Investments	0.45	0.05	0.09	0.66	-0.04	-0.38	0.08	0.64	0.63	0.16	0.58	0.59	0.15	-0.35	0.31	-0.13	0.36	-0.11	-0.76	-0.5	0.71	0.02	-0.55	0.46		0.42
Other Assets	0.14	-0.17	-0.11	0.19	-0.16	0.49	0.15	0.17	0.32	-0.05	0.06	0.34	-0.51	-0.08	0.09	-0.33	0.42	-0.34	-0.2	-0.04	0.29	-0.35	-0.17	-0.4	0.42

Click cells to compare fundamentals

Edesa Biotech Account Relationship Matchups

Edesa Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Liab	1.5M	1.4M	2.1M	1.7M	2.0M	1.2M
Total Current Liabilities	1.5M	1.5M	2.1M	1.8M	2.1M	1.3M
Total Stockholder Equity	6.6M	13.1M	9.4M	7.0M	8.1M	6.4M
Net Debt	(7.0M)	(7.7M)	(7.1M)	(5.3M)	(4.7M)	(5.0M)
Retained Earnings	(13.1M)	(26.5M)	(44.0M)	(52.4M)	(47.2M)	(44.8M)
Cash	7.2M	7.8M	7.1M	5.4M	6.2M	5.6M
Non Current Assets Total	2.7M	2.5M	2.5M	2.5M	2.8M	3.0M
Cash And Short Term Investments	7.2M	7.8M	7.1M	5.4M	6.2M	6.8M
Common Stock Shares Outstanding	8.6M	12.1M	16.7M	20.0M	23.0M	24.2M
Liabilities And Stockholders Equity	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Assets	890.3K	948.6K	2.0M	448.9K	516.2K	429.9K
Other Stockholder Equity	1.3M	4.7M	11.2M	13.0M	15.0M	15.7M
Total Liab	4.1M	1.5M	2.2M	1.8M	2.1M	2.3M
Total Current Assets	8.1M	12.1M	9.1M	6.4M	7.4M	7.6M
Property Plant And Equipment Net	174.8K	111.6K	31.2K	100.1K	90.1K	85.6K
Net Receivables	87.4K	3.3M	1.3M	626.5K	720.5K	521.2K
Property Plant And Equipment Gross	174.8K	145.4K	70.7K	143.9K	129.5K	123.1K
Accumulated Other Comprehensive Income	(287.2K)	(205.3K)	(213.6K)	(214.6K)	(193.2K)	(202.8K)
Non Current Liabilities Total	2.6M	67.7K	43.7K	19.8K	17.8K	16.9K
Inventory	224.3K	(217.1K)	(87.4K)	(1.3M)	(1.1M)	(1.1M)
Common Stock	18.5M	34.9M	42.5M	46.6M	53.6M	39.4M
Property Plant Equipment	73.1K	174.8K	111.6K	31.2K	28.0K	26.6K
Net Tangible Assets	5.3M	4.1M	10.7M	7.1M	8.2M	4.3M
Accounts Payable	424.6K	1.5M	1.4M	2.1M	2.4M	2.6M
Net Invested Capital	6.6M	13.1M	9.4M	7.0M	8.1M	9.4M
Net Working Capital	6.6M	10.6M	7.0M	4.6M	4.2M	5.8M
Capital Stock	18.5M	34.9M	42.5M	46.6M	53.6M	38.7M

Pair Trading with Edesa Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Edesa Stock

0.64	MRNA	Moderna Financial Report 2nd of May 2024	Pair Corr
0.5	BMY	Bristol Myers Squibb Financial Report 25th of April 2024	Pair Corr
0.48	CELC	Celcuity LLC Financial Report 20th of May 2024	Pair Corr
0.44	INDP	Indaptus Therapeutics Financial Report 9th of May 2024	Pair Corr

The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.

The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:

How To Invest In Edesa

Details

Is Edesa Stock a good investment?

Details

What is Edesa Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Edesa Stock analysis

When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.

	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Commodity Directory Find actively traded commodities issued by global exchanges
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.

Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(20.16)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.56)

Return On Equity

(0.96)

The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edesa Income Tax Expense vs Gross Profit Analysis

Income Tax Expense vs Gross Profit

Income Tax Expense vs Gross Profit Correlation Analysis

Correlation Coefficient

Income Tax Expense

Gross Profit

Edesa Biotech fundamental ratios Correlations

Edesa Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edesa Biotech fundamental ratios Accounts

Pair Trading with Edesa Biotech

Moving against Edesa Stock

Complementary Tools for Edesa Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Liabilities	+ 0.99	Other Current Liab
Total Current Assets	+ 0.97	Total Assets
Total Current Assets	+ 0.96	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.96	Total Liab
Common Stock Shares Outstanding	+ 0.95	Non Currrent Assets Other

Cash	- 0.99	Net Debt
Common Stock	- 0.93	Retained Earnings
Inventory	- 0.91	Common Stock Shares Outstanding
Inventory	- 0.89	Non Currrent Assets Other
Total Current Assets	- 0.83	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt